AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

EMBC · NASDAQ · Medical - Instruments & Supplies

Embecta (EMBC)

Sells pen needles, syringes, and newer drug-delivery devices for diabetes and chronic care.

$5.59

After hours−0.01 (−0.18%)

At close$5.60(+5.66%)

In millions of USD, except per-share figures

In millions	Q4 FY23Sep 2023	Q1 FY24Dec 2023	Q2 FY24Mar 2024	Q3 FY24Jun 2024	Q4 FY24Sep 2024	Q1 FY25Dec 2024	Q2 FY25Mar 2025	Q3 FY25Jun 2025	Q4 FY25Sep 2025	Q1 FY26Dec 2025	Q2 FY26Mar 2026	Q3 FY26Jun 2026
Revenue	282	277	287	273	286	262	259	296	264	261	222	272
Cost of revenue	100	91	103	85	115	95	98	101	108	86	97	118
Gross profit	182	186	184	188	171	167	162	195	156	176	125	153
	150	139	145	132	138	90	83	89	92	79	82	105
Research & development	24	20	18	20	20	10	4	4	5	0	10	6
Selling, general & administrative	96	90	92	86	97	81	79	84	87	78	76	0
Other expenses	31	28	34	26	21	0	0	1	0	1	−4	99
Operating income	32	47	39	56	34	77	79	106	64	97	43	49
	−27	−33	−29	−29	−41	−78	−43	−34	−35	−38	−33	−21
Interest expense	28	28	28	28	29	28	27	27	26	24	23	24
Other non-operating income	−1	5	2	1	12	50	16	7	9	14	11	−3
Income before tax	5	14	10	27	−7	−1	36	72	29	59	10	28
Income tax expense	−1	−6	−19	12	−22	−1	12	27	3	15	14	7
Net income from continuing operations	6	20	29	15	15	0	24	46	26	44	−4	21
Other adjustments	0	0	0	0	0	−1	0	0	0	0	0	0
Net income	6	20	29	15	15	−1	24	46	26	44	−4	21
EPS, basic	$0.10	$0.35	$0.50	$0.25	$0.25	−$0.01	$0.40	$0.78	$0.45	$0.75	−$0.07	$0.36
EPS, diluted	$0.10	$0.35	$0.50	$0.25	$0.25	−$0.01	$0.40	$0.78	$0.45	$0.74	−$0.07	$0.36
Weighted average shares, basic	57	57	58	58	58	58	58	58	58	58	58	58
Weighted average shares, diluted	57	58	58	58	58	59	59	58	59	59	59	59
EBITDA	42	51	48	66	34	39	74	111	71	96	45	62
Depreciation & amortization	9	9	10	11	12	12	12	12	16	13	13	11
EBIT	33	42	38	55	22	27	63	99	55	83	32	52